Previous Registries

Secure: A Non-Interventional Long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia®) for Crohn's Disease

  • Sponsor: UCB Biosciences Inc.
  • Disease: Crohn’s Disease
  • Study Drug: Cimzia

PASS: Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn’s Disease.

  • Sponsor: Takeda
  • Disease: Ulcerative colitis and Crohn’s Disease
  • Study Drug: Vedolizumab

Legacy: A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)

  • Sponsor: AbbVie
  • Disease: Moderate/Severe Crohn’s Disease
  • Study Drug: HUMIRA® (adalimumab)